- Unique partnership with Medtronic will enable continuous
glucose monitoring (CGM) sensors based on Abbott's FreeStyle Libre
sensing technology to integrate with Medtronic's insulin delivery
systems
- Abbott now has partnerships with four of the largest companies
that develop automated insulin delivery systems – offering more
choices to people around the world to benefit from connectivity
with Libre technology
ABBOTT PARK, Ill., Aug. 7, 2024
/PRNewswire/ -- Abbott (NYSE: ABT) today announced a unique global
partnership with Medtronic to collaborate on an integrated
continuous glucose monitoring (CGM) system based on Abbott's most
advanced, world-leading1 FreeStyle Libre technology that
will connect with Medtronic's automated insulin delivery (AID) and
smart insulin pen systems.
The integration of Abbott's CGM sensor with
Medtronic's AID algorithms will enable automatic
adjustments of insulin to keep glucose in range. The CGM
sensor, designed to work exclusively with Medtronic devices, will
be developed by Abbott and sold by Medtronic.
AID systems improve health outcomes while reducing the burden of
constant decision-making for people with diabetes who use intensive
insulin as part of their overall therapy. AID systems can benefit
people with both Type 1 and Type 2 diabetes who require multiple
daily injections of rapid-acting insulin, currently estimated at
more than 11 million people globally2.
Financial terms of the partnership and timing for commercial
availability were not disclosed.
"This partnership pairs two global leaders in glucose sensing
technology and insulin delivery," said Jared Watkin, executive vice president of
Abbott's diabetes care business. "Libre technology has set the
standard for accurate, accessible, easy-to-use and
reliable continuous glucose monitoring. Connecting this CGM
built for Medtronic's insulin delivery systems and algorithms makes
it easier for people to spend less time thinking about their
diabetes and more time living."
"Our partnership with Abbott allows us to expand access to our
advanced automated insulin delivery and smart MDI systems that
deliver best-in-class outcomes with the most widely used CGM in the
world," said Que Dallara, executive vice president and president,
Medtronic Diabetes. "We're committed to simplifying diabetes
management and making the transition to automated technology much
more seamless for those who wish to achieve more with their
diabetes care."
This collaboration with Medtronic is the latest in a series of
Abbott partnerships aimed at improving and streamlining diabetes
care, giving people more choices to confidently administer their
insulin. Abbott's Libre single-analyte CGM technology is currently
available and integrated with AID offerings from other insulin
delivery companies.
About Abbott's Libre Systems
Abbott's Libre portfolio
is the world's leading continuous glucose monitoring
technology1, now used by more than 6 million people in
more than 60 countries3. Clinical and real-world
data from the millions of people that use Libre systems show that
the technology helps people improve their glucose control,
lower their HbA1c, decrease diabetes-related hospital admissions,
and improve their quality of life4,5. The systems have
partial or full reimbursement in more than 40 countries.
For important safety information, visit
https://www.freestylelibre.us/safety-information.html
About Abbott:
Abbott is a global healthcare leader that helps people live more
fully at all stages of life. Our portfolio of life-changing
technologies spans the spectrum of healthcare, with leading
businesses and products in diagnostics, medical devices,
nutritionals and branded generic medicines. Our 114,000 colleagues
serve people in more than 160 countries. Connect with us
at www.abbott.com and
on LinkedIn, Facebook, Instagram, X and YouTube.
- Data on file, Abbott Diabetes Care. Based on the number of
patients assigned to each manufacturer.
- Fortune Business Insights: Top Reasons Driving the Demand for
Insulin Pumps, 2021
- Data on file, Abbott Diabetes Care.
- The American Journal of Managed Care, Flash CGM Associated With
Event Reduction in Nonintensive Diabetes Therapy, 2021.
- American Diabetes Association, Continuous Glucose Monitors,
accessed March 20, 2024.
Logo -
https://mma.prnewswire.com/media/271488/Abbott_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/abbott-enters-global-partnership-to-connect-its-world-leading-continuous-glucose-monitoring-system-with-medtronics-insulin-delivery-devices-302216502.html